HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.5%

Neg 0% Neu 91.5% Pos 0%

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $145 price target.